Rocket Pharmaceuticals Completes Acquisition of Renovacor
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company’s chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentation at the 29th European Society of Gene & Cell Therapy (ESGCT) Congress. The congress is taking place from October 11 – 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference. The conference is taking place from September 28 – October 1, 2022, at the Beaver Run Resort in Breckenridge, CO.
Rocket Pharmaceuticals is set to snap up gene therapy startup Renovacor, inking an all-stock merger that will give it control of a preclinical heart disease candidate and add $38 million to its cash reserves.
Shares of Renovacor, Inc. are surging in premarket trading following Rocket Pharmaceuticals' announcement it will acquire the company in an all-stock transaction valued at $53 million. The deal bolsters Rocket’s ability to treat cardiac-related maladies.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the second quarter of 2022 and provided a corporate update.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI). The terms of the research agreement grant Renovacor an option for an exclusive license to inventions generated from the collaboration.